The role of inflammation in lymphoma.
Carbone A
Adv Exp Med Biol. 816:315-33. doi: 10.1007/978-3-0348-0837-8_12
Targeting TRAIL agonistic receptors for cancer therapy.
Carlo-Stella C
Clin Cancer Res. 13(8):2313-7.
Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy.
Siena S
J Clin Oncol. 18(6):1360-77.
The new refined minnesota risk score for acute graft-versus-host disease predicts overall survival and non-relapse mortality after T cell-replete haploidentical stem cell transplant with post-transplant cyclophosphamide.
Mariotti J
Bone Marrow Transplant. 2019 Jan 24;54(7):1164-1167. doi: 10.1038/s41409-019-0453-0
Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma.
Mariotti J
Bone Marrow Transplant. 2017 Dec 21;53(3):366-370. doi: 10.1038/s41409-017-0032-1
T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for Hodgkin Lymphoma Relapsed after Autologous Transplantation: Reduced Incidence of Relapse and of Chronic Graft-versus-Host Disease Compared with HLA-Identical Related Donors.
Mariotti J
Biol Blood Marrow Transplant. 2017 Nov 29;24(3):627-632. doi: 10.1016/j.bbmt.2017.11.030
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S
Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2
The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest.
Locatelli SL
Leukemia. 2016 Aug 8;30(12):2402-2405. doi: 10.1038/leu.2016.224
The patient’s CMV serological status affects clinical outcome after T-cell replete haplo-HSCT and post-transplant cyclophosphamide.
Crocchiolo R
Bone Marrow Transplant. 2016 Mar 21;51(8):1134-6. doi: 10.1038/bmt.2016.69
Tacrolimus compared with cyclosporine A after haploidentical T-cell replete transplantation with post-infusion cyclophosphamide.
Castagna L
Bone Marrow Transplant. 51(3):470. doi: 10.1038/bmt.2015.327